Antigen-binding proteins

Patent metadata

Field	Value
Publication number	US-9394374-B2
Application number	US-201013322224-A
Country	US
Kind code	B2
Filing date	May 26, 2010
Priority date	May 28, 2009
Publication date	Jul 19, 2016
Grant date	Jul 19, 2016

Abstract

The invention relates to linkers suitable for use in antigen-binding proteins, certain antigen binding proteins and methods of making such proteins and uses thereof.

First claim

The invention claimed is:

1. An antigen-binding protein comprising a protein scaffold which is linked to one or more epitope-binding domains wherein the antigen-binding protein has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain wherein the epitope binding domain is linked to the protein scaffold by a linker comprising SEQ ID NO: 78.

2. An antigen-binding protein according to claim 1 wherein the linker is (TGLDSP) n (GS) m , wherein n=1-10, and m=0-4.

3. The antigen-binding protein according to claim 1 wherein at least one epitope binding domain is an immunoglobulin single variable domain.

4. The antigen-binding protein according to claim 3 wherein the immunoglobulin single variable domain is a human dAb.

5. The antigen-binding protein of claim 1 wherein the antigen binding protein has specificity for more than one antigen.

6. The antigen-binding protein according to claim 1 wherein the first binding site has specificity for a first epitope on an antigen and the second binding site has specificity for a second epitope on the same antigen.

7. The antigen-binding protein according to claim 1 wherein the antigen-binding protein is capable of binding IL-13 or TNFα or IL1-R.

8. The antigen-binding protein according to claim 1 wherein the antigen-binding protein is capable of binding two or more antigens selected from IL-13, IL-5, and IL-4, VEGF, IGF-1R and EGFR.

9. The antigen-binding protein according to claim 1 wherein the protein scaffold is an Ig scaffold.

10. The antigen-binding protein according to claim 1 wherein at least one of the epitope binding domains binds human serum albumin.

11. A pharmaceutical composition comprising an antigen binding protein of claim 1 and a pharmaceutically acceptable carrier.

12. The antigen-binding protein according to claim 2 wherein at least one epitope binding domain is an immunoglobulin single variable domain.

13. The antigen-binding protein according to claim 12 wherein the immunoglobulin single variable domain is a human dAb.

14. The antigen-binding protein of claim 2 wherein the antigen binding protein has specificity for more than one antigen.

15. The antigen-binding protein according to claim 2 wherein the first binding site has specificity for a first epitope on an antigen and the second binding site has specificity for a second epitope on the same antigen.

16. The antigen-binding protein according to claim 2 wherein the antigen-binding protein is capable of binding IL-13 or TNFα or IL1-R.

17. The antigen-binding protein according to claim 2 wherein the antigen-binding protein is capable of binding two or more antigens selected from IL-13, IL-5, and IL-4, VEGF, IGF-1R and EGFR.

18. The antigen-binding protein according to claim 2 wherein the protein scaffold is an Ig scaffold.

19. The antigen-binding protein according to claim 2 wherein at least one of the epitope binding domains binds human serum albumin.

20. A pharmaceutical composition comprising an antigen binding protein of claim 2 and a pharmaceutically acceptable carrier.

21. An antigen-binding protein comprising a protein scaffold which is linked to one or more epitope-binding domains wherein the antigen-binding protein has at least two antigen binding sites at least one of which is from an epitope binding domain and at least one of which is from a paired VH/VL domain wherein the epitope binding domain is linked to the protein scaffold by a linker comprising SEQ ID NO: 77.

22. An antigen-binding protein according to claim 21 wherein the linker is (TVSDVP) n (GS) m , wherein n=1-10, and m=0-4.

23. The antigen-binding protein according to claim 21 wherein at least one epitope binding domain is an immunoglobulin single variable domain.

24. The antigen-binding protein according to claim 23 wherein the immunoglobulin single variable domain is a human dAb.

25. The antigen-binding protein of claim 21 wherein the antigen binding protein has specificity for more than one antigen.

26. The antigen-binding protein according to claim 21 wherein the first binding site has specificity for a first epitope on an antigen and the second binding site has specificity for a second epitope on the same antigen.

27. The antigen-binding protein according to claim 21 wherein the antigen-binding protein is capable of binding IL-13 or TNFα or IL1-R.

28. The antigen-binding protein according to claim 21 wherein the antigen-binding protein is capable of binding two or more antigens selected from IL-13, IL-5, and IL-4, VEGF, IGF-1R and EGFR.

29. The antigen-binding protein according to claim 21 wherein the protein scaffold is an Ig scaffold.

30. The antigen-binding protein according to claim 21 wherein at least one of the epitope binding domains binds human serum albumin.

31. A pharmaceutical composition comprising an antigen binding protein of claim 21 and a pharmaceutically acceptable carrier.

32. The antigen-binding protein according to claim 22 wherein at least one epitope binding domain is an immunoglobulin single variable domain.

33. The antigen-binding protein according to claim 22 wherein the immunoglobulin single variable domain is a human dAb.

34. The antigen-binding protein of claim 22 wherein the antigen binding protein has specificity for more than one antigen.

35. The antigen-binding protein according to claim 22 wherein the first binding site has specificity for a first epitope on an antigen and the second binding site has specificity for a second epitope on the same antigen.

36. The antigen-binding protein according to claim 22 wherein the antigen-binding protein is capable of binding IL-13 or TNFα or IL1-R.

37. The antigen-binding protein according to claim 22 wherein the antigen-binding protein is capable of binding two or more antigens selected from IL-13, IL-5, and IL-4, VEGF, IGF-1R and EGFR.

38. The antigen-binding protein according to claim 22 wherein the protein scaffold is an Ig scaffold.

39. The antigen-binding protein according to claim 22 wherein at least one of the epitope binding domains binds human serum albumin.

40. A pharmaceutical composition comprising an antigen binding protein of claim 22 and a pharmaceutically acceptable carrier.

Assignees

• Hamblin Paul Andrew
• Lewis Alan Peter
• Orecchia Martin Anibal
• Parmar Radha Shah
• Glaxo Group Ltd

Inventors

• Hamblin Paul Andrew
• Lewis Alan Peter
• Orecchia Martin Anibal
• Parmar Radha Shah

Classifications

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P11/06

  Antiasthmatics · CPC title

• A61P19/02

  for joint disorders, e.g. arthritis, arthrosis · CPC title

• C07K16/247

  IL-4 · CPC title